Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Jefferson Research
$20.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Covidien PLC releases two-year study results demonstrating sustained effectiveness of drug-coated Angioplasty Balloon Technology


Thursday, 22 May 2014 05:16am EDT 

Covidien PLC:Says its' Stellarex drug-coated angioplasty balloon (Stellarex DCB) continues to be shown as safe and effective for treatment of peripheral arterial disease (PAD), according to new 24-month data released from its ILLUMENATE First-in-Human (FIH) Study.FIH study results were reported at the EuroPCR Scientific Congress in Paris, held May 20-23.The ILLUMENATE FIH study is a prospective, multi-center, single arm study designed to assess the safety and effectiveness of the Stellarex DCB.In the study, 58 superficial femoral and/or popliteal lesions in 50 patients were pre-dilated with an uncoated angioplasty balloon, followed by treatment with the Stellarex DCB. 

Related Company News

Company Quote

103.21
-0.14 -0.14%
26 Dec 2014